Sorry, you are not eligible to join this program.
Currently Wegovy® (semaglutide) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for patients with an initial BMI ≥27 kg/m2 to <30 kg/m2 with the presence of at least one other weight-related medical condition.
If you have any questions about your prescription please contact your prescriber.
For all other queries, please contact Novo Nordisk® Medical Information on 1800 668 626 or aunrccc@novonordisk.com.
Sorry, you are not eligible to join this program.
Currently Wegovy® (semaglutide) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial obesity (BMI ≥ 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) and a body weight above 60kg.
If you have any questions about your prescription please contact your prescriber. For all other queries, please contact Novo Nordisk® Medical Information on 1800 668 626 or aunrccc@novonordisk.com.
Sorry, you are not eligible to join this program.
Currently Wegovy® (semaglutide) is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a Body Mass Index (BMI) ≥27 kg/m2, and without established Type 1 or Type 2 diabetes.
If you have any questions about your prescription please contact your prescriber.
For all other queries, please contact Novo Nordisk® Medical Information on 1800 668 626 or aunrccc@novonordisk.com